research:project_proposal_template
Differences
This shows you the differences between two versions of the page.
| Both sides previous revision Previous revision Next revision | Previous revision | ||
|
research:project_proposal_template [2014/12/02 18:12] jduke |
research:project_proposal_template [2015/02/16 20:45] (current) rkboyce |
||
|---|---|---|---|
| Line 1: | Line 1: | ||
| - | ====== Treatment Pathways in Hypertension ====== | + | ====== Incidence of exposure to drugs for which pre-emptive pharmacogenomic testing is available ====== |
| <WRAP box justify round> | <WRAP box justify round> | ||
| - | **Objective:** //<summarize study objective>// | + | **Objective:** Derive data that large healthcare organizations can combine data on risks of adverse events and cost data to conduct cost-effectiveness / cost-benefit analyses for pre-emptive pharmacogenomics testing |
| - | **Rationale:** //<summarize study rationale>// | + | **Rationale:** Very few studies have been conducted that report on the potential return on investment for pre-emptive pharmacogenomics testing. The studies that have been published suggest that pre-emptive pharmacogenomics testing may produce a return on investment but much depends on if a sufficient number of drugs with pharmacogenes are covered by a single test. Since the current data are limited to relatively localized settings and might not be of generalizable use to other health organizations, it's of interest to implement a new study using the OHDSI research network. |
| - | **Project Lead(s):** //<initial proposers, list may grow>// | + | **Project Lead(s):** Richard D. Boyce, Matthias Samwald, Patrick Ryan, (seeking other collaborators) |
| - | **Coordinating Institution(s):** //<your institution>// | + | **Coordinating Institution(s):** University of Pittsburgh, Medical University of Vienna |
| ** Additional Participants:** //<usually blank initially, list will grow as individuals are added who are not project leads>// | ** Additional Participants:** //<usually blank initially, list will grow as individuals are added who are not project leads>// | ||
| Line 15: | Line 15: | ||
| **Full Protocol:** //<if available, a link to protocol. not necessary for initial planning>// | **Full Protocol:** //<if available, a link to protocol. not necessary for initial planning>// | ||
| - | **Initial Proposal Date:** | + | **Initial Proposal Date:** 2/16/2015 |
| **Launch Date:** //<fill out once finalized>// | **Launch Date:** //<fill out once finalized>// | ||
| Line 26: | Line 26: | ||
| ===== Requirements ===== | ===== Requirements ===== | ||
| - | **CDM:** //<V4 or V5 or both>// | + | **CDM:** V4 or V5 |
| - | **Table Accessed:** //<e.g., person, drug_exposure, observations>// | + | **Table Accessed:** DRUG_EXPOSURE, CONCEPT_ANCESTOR, CONCEPT_RELATIONSHIP, PERSON |
| **Database Dialects:** SQL Server, Postgres, Oracle | **Database Dialects:** SQL Server, Postgres, Oracle | ||
| - | **Software:** //<<e.g., R>// | + | **Software:** SQL and R |
| ===== Code ===== | ===== Code ===== | ||
| - | [[https://github.com/OHDSI/StudyProtocols]] | + | [[https://github.com/OHDSI/StudyProtocols/tree/master/Proposed%20Study%203%20-%20Incidence%20of%20exposure%20to%20PGx%20drugs|GitHub code for Proposed Study 3 - Incidence of exposure to PGx drugs]] |
| ===== Discussion ===== | ===== Discussion ===== | ||
| - | [[http://forums.ohdsi.org/t/test-post-for-the-ohdsi-research-network/101/1|Hypertension Pathways Thread]] | + | //Post a thread letting everyone know about this new proposed study at [[http://forums.ohdsi.org/c/researchers]]// |
| ===== Datasets Run ===== | ===== Datasets Run ===== | ||
| - | * Truven | + | * Truven CCAE in the IMEDS lab |
| - | * Optum | + | * Truven MDCD in the IMEDS lab |
| - | * CPRD | + | * Truven MDCR in the IMEDS lab |
| - | * Indiana Network for Patient Care | + | |
| ~~NOTOC~~ | ~~NOTOC~~ | ||
research/project_proposal_template.1417543952.txt.gz · Last modified: 2014/12/02 18:12 by jduke
Page Tools
